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The concept of ideal cardiovascular (CV) health, with 
emphasis on the prevention of CV disease (CVD), was in-
cluded by the American Heart Association (AHA) among its 
strategic goals for 2020 [1]. This concept was intended to 
focus mainly on the promotion of a healthy lifestyle and the 
adoption of a multifactorial intervention with non-
pharmacological or pharmacological means, aiming at the 
prevention or the effective control of CVD risk factors [1]. 
Ideal CV health is defined as optimal levels of 3 CVD risk 
factors [blood pressure (BP), fasting plasma glucose and 
total cholesterol) and 4 behaviours [body mass index (BMI), 
smoking, physical activity and healthy diet] [1]. These 7 
ideal CV metrics, called life's simple 7, are probably the best 
available markers of life-time CVD risk [2]. Recent studies 
have shown that the levels of ideal CV health in the United 
States to be very low at a community level [3-5] and to be 
associated with cardiac events [3], stroke [2] and total mor-
tality [6]. A large study was conducted in 5,785 young adults 
(20-39 years old) from 5 international populations: the Min-
neapolis Childhood Cohort Study, the Princeton Follow-up 
Study, the Bogalusa Heart Study, the Cardiovascular Risk in 
Young Finns Study, and the Childhood Determinants of 
Adult Health (CDAH) Study; all members of the Interna-
tional Childhood Cardiovascular Cohort (i3C) Consortium 
[7]. Results of the study showed that ideal CV health, as de-
fined by the AHA, was rare among young participants of the 
study. An amazingly low (only 1%) percentage of the par-
ticipants had all 7 health metrics in the 5,785 young adults 
participating from all international cohorts [7]. Many of the 
participants had ideal glucose (73%), cholesterol (64%), and 
were non-smokers (64%); diet (7%) was the least common 
metric for participants from any of the cohorts [7]. The low-
est prevalence of a clinical CVD risk factor from the life's 7 
simple was BP; this was normal in only 52% of the  
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participants [7]. The National and Nutrition Exami-
nation Surveys (NHANES) 2003-2008 evaluated the preva-
lence of the 7 CV health metrics in 14,515 adults [8]. Par-
ticipants were stratified in young (20-39 years), middle-aged 
(40-64 years) and elderly ( 65 years). Less than 1% of sub-
jects exhibited CV for all 7 . Among 
CV behaviors, non-smoking was the most prevalent 
(60.2-90.4%), Healthy Diet Score was least prevalent 
(0.2-2.6%) across groups, while  (36.5-45.3%) 
and physical activity levels (50.2-58.8%) were higher 
in young adults compared with middle-aged or elderly [8]. 
total cholesterol (23.7-36.2%), blood pressure (11.9%-
16.3%), and fasting blood glucose (31.2-42.9%) were less 
frequent in older adults compared with young and middle-
aged adults. The prevalence of poor CV status was 
lowest in young age compared with higher middle and older 
ages [8]. Again, ideal BP was the least prevalent among 
clinical CVD risk factors [8].  
A relevant Chinese study included 91,698 participants 
(72,826 men, age 18-98 years-old), free of myocardial in-
farction and stroke at baseline (2006-2007) [2]. The hazard 
ratios (HR) and 95% confidence interval (CI) for total stroke 
according to the adherence to life's 7 simple [0 (reference), 1, 
2, 3, 4, 5, and 6/7 ideal CV metrics] were: 1, 0.92 (0.69-
1.23), 0.69 (0.52-0.92), 0.52 (0.39-0.68), 0.38 (0.28-0.51), 
0.27 (0.18-0.40), and 0.24 (0.11-0.54), respectively (p for 
trend <0.01), after adjusting for age, sex, education, income 
and hospital [2]. Similar inverse associations were observed 
for both ischaemic and haemorrhagic stroke (p for trend 
<0.01) [2]. In this study, high BP played a major role in 
stroke incidence [2]. 
The above data suggest that in the effort of achieving 
ideal CV health, hypertension should be one of the primary 
targets, because of its high prevalence in the general popula-
tion and the low levels of effective control [9]. Moreover, if 
we can control BP and improve some of the other CV met-
rics of ideal CV health, this will have significant additive 
beneficial effects. 
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Non-pharmacological interventions to control hyperten-
sion or to augment the effects of antihypertensive drug 
treatment (thereby potentially reducing the need for more 
drugs), have been used for a long time [10,11]. The recent 
(2013) ESH/ESC Guidelines for the management of hyper-
tension [12] suggest: salt restriction to 5-6 g/d, moderation of 
alcohol consumption to <20-30 g/d of ethanol in men and 
<10-20 g/d in women, increased consumption of vegetables, 
fruits, and low-fat dairy products, reduction of BMI to <25 
kg/m
2
 and of waist circumference to <102 cm in men and 
<88 cm in women, regular exercise (at least 30 min of mod-
erate dynamic exercise on 5 to 7 days per week), and ad-
vice/support for smoking cessation [12]. Moreover, high 
quality evidence suggests that increased potassium intake is 
beneficial in most adults without impaired renal handling of 
potassium for the prevention or control of elevated BP and 
prevention of stroke (reduction of incidence by 24%), with-
out adverse effects on lipid concentrations, catecholamine 
concentrations or renal function [13]. However, compliance 
to long-term lifestyle changes to treat hypertension is very 
low, and special programs and interventions to improve this 
adherence may need to consider the existing barriers [14]. A 
low desire, interest or awareness are commonly reported 
barriers to salt restriction, changes in diet, weight loss, smok-
ing cessation and alcohol reduction [14]. In contrast, the 
most common barrier to engaging in physical activity to 
regulate BP is time limitations and the challenge of manag-
ing a co-existing physical condition/disease; arthritis (60%), 
back problems (41%), diabetes (27%), CVD or stroke (27%), 
asthma (23%) and chronic obstructive pulmonary disease 
(22%) [14]. Thus, non-pharmacological interventions for the 
treatment of hypertension are not successful enough [15]. 
A number of studies have demonstrated the protective ef-
fects of foods rich in polyphenols (fruit, tea, wine and cocoa 
or chocolate and especially citrus fruit) against several CVD 
risk factors such as hypertension, low density lipoprotein 
(LDL) particle oxidation and endothelial dysfunction [16-
18]. The pomegranate tree (Punica granatum), considered to 
be originated in the Garden of Eden (modern Mesopotamia 
and specifically Iran), has been extensively used as a folk 
medicine in many cultures [19]. Today, it is widely culti-
vated throughout the Mediterranean region of southern 
Europe, the Middle East and the Caucasus region, northern 
and tropical Africa, the Indian subcontinent and the drier 
parts of Southeast Asia [19]. Introduced into Latin America 
and California by Spanish settlers in 1769, pomegranate is 
also cultivated in parts of California and Arizona. Edible 
parts of pomegranate fruits (about 50% of total fruit weight) 
comprise 80% juice and 20% seeds. Fresh juice contains 
85% moisture, 10% total sugars, 1.5% pectin, ascorbic acid 
and polyphenols [19]. Pomegranate fruit is considered as a 
heart-healthy fruit [19,20]. Pomegranate is rich in polyphe-
nolic-type antioxidants, including tannins, anthocyanins and 
several other types of flavonoids [20,21]. The soluble poly-
phenol content in pomegranate juice (PJ) normally ranges 
between 0.2 and 1.0% depending on the fruit variety, and 
mainly comprises tannins, ellagic anthocyanins, catechins, 
and gallic and ellagic acids [20,21]. Despite the previously 
reported CV health benefits of pomegranate and its high con-
tent in polyphenols and flavonoids [20-22], there have been 
very few studies on the anti-hypertensive effects of PJ [23]. 
A very recent study included 21 hypertensive patients (aged 
30-67 years) [23]. These were assigned to receive either PJ 
(150 ml/day in a single occasion between lunch and dinner; n 
= 11) or the same amount of water (n = 10) for a period of 2 
weeks. PJ consumption was associated with significant re-
ductions in systolic BP (p=0.002) and diastolic BP 
(p=0.038), but not flow mediated dilation (FMD)  (p>0.05). 
Serum levels of vascular cell adhesion molecule 1 (VCAM-
1) (p=0.008) were significantly reduced by PJ while those of 
E-selectin were elevated (p=0.039). However, no significant 
PJ effect was observed on serum levels of intercellular adhe-
sion molecule 1 (ICAM-1), high-sensitivity C-reactive pro-
tein (hs-CRP), lipid profile, and interleukin-6; this null effect 
might be due to the short duration of the study [23]. There-
fore, consumption of PJ for 2 weeks has effective hypoten-
sive action and may also improve endothelial function. 
These findings suggest PJ as a beneficial cardioprotective 
supplement for hypertensive subjects, with actions extending 
beyond BP reduction [23]. In an earlier (2001) study in hy-
pertensive patients, the consumption of PJ (50 ml, 1.5 mmol 
of total polyphenols per day, for 2 weeks) decreased serum 
angiotensin converting enzyme (ACE) activity by 36% and 
systolic BP by 5% [24]. Similar inhibitory effect (31%) of PJ 
on serum ACE activity was also observed in vitro [24]. Since 
a reduction in serum ACE activity was previously shown to 
attenuate atherosclerosis, PJ can offer protection against 
CVD, which could also be related to its inhibitory effect on 
oxidative stress [24]. Another study demonstrated reduced 
BP in patients with carotid artery stenosis who had con-
sumed pomegranate juice for 3 years [25]. Ten patients were 
given PJ for 1 year with 5 patients continuing consumption 
for up to 3 years. Systolic BP was reduced by 21% after 1 
year of PJ consumption and was not further reduced during 
the 3 years of PJ use [25]. In this study, serum paraoxonase-
1 (PON-1) activity was increased by 83%, whereas serum 
LDL basal oxidative state and LDL susceptibility to copper 
ion-induced oxidation were both significantly reduced by 
90% and 59%, respectively, after 12 months of PJ consump-
tion [25]. Furthermore, serum levels of antibodies against 
oxidized LDL were decreased by 19%, and in parallel serum 
total antioxidant status was increased by 130% after 1 year 
of PJ consumption [25]. In the control group, common ca-
rotid intima-media thickness (cIMT) increased by 9% during 
1 year, whereas PJ consumption resulted in a significant 
cIMT reduction, by up to 30%, after 1 year [25]. For all stud-
ied parameters, the maximal effects were observed after 1 
year of PJ consumption. Further consumption of PJ, for up to 
3 years, had no additional beneficial effects on IMT and se-
rum PON-1 activity, whereas serum lipid peroxidation was 
further reduced by up to 16% after 3 years of PJ consump-
tion [25]. Total and LDL cholesterol were not significantly 
affected. Regarding the effect of PJ on triglycerides (TGs), 
recent data suggest an inhibitory activity of PJ on TGs bio-
synthesis, which could be attributed to a direct effect of PJ 
on diacylglycerol acyltransferase 1 (DGAT1) activity [26]. 
In a larger study in subjects with moderate coronary heart 
disease risk, PJ consumption (240 ml/day, n=146) or a con-
trol beverage (n=143) for up to 18 months had no significant 
effect on overall cIMT progression rate, but may have 
slowed cIMT progression in subjects with increased oxida-
tive stress and abnormalities in the TG-rich lipoprotein/ 
high-density lipoprotein (HDL) axis [27]. Regarding HDL, 
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the association of PON-1 with HDL stabilizes this antioxi-
dant enzyme. In high-risk patients, especially those with dia-
betes, PON-1 dissociates from HDL and, as a consequence, 
becomes less active [28]. PJ consumption augments PON-11 
stability and increases its activity; this could lead to retarda-
tion of atherosclerosis development [28], especially PJ from 
the "wonderful" variety of the fruit [29]. Overall, PJ has at 
least 20% greatest antioxidant potency than a variety of other 
antioxidant beverages, including apple juice, açaí juice, 
black cherry juice, blueberry juice, cranberry juice, Concord 
grape juice, orange juice, black tea, green tea and white tea 
[30]. Similar benefits ofPJ consumption were observed in 
diabetic patients. Indeed, PJ consumption by diabetic pa-
tients resulted in anti-oxidative effects on serum and macro-
phages without worsening glycemic control [31]. Moreover, 
arterial stiffness of the common carotid arteries in 73 pa-
tients with at least one CVD risk factor that consumed PJ 
("wonderful" variety, 240 mL/d for 1 year) showed trends to 
increased elasticity in the PJ-treated group versus the pla-
cebo-treated group (who received a beverage of similar ca-
loric content, flavor and color) [19]. However, a single dose 
of PJ following a high-fat meal had no effect on reflection 
index, stiffness index or diastolic BP, but lowered post-
prandial plasma TGs concentrations and suppressed the 
postprandial increase in systolic BP following the high-fat 
meal [32]. 
Beyond hypertension, oxidative stress is also causally re-
lated with several CVD risk factors such as diabetes, dyslipi-
daemia, metabolic syndrome and smoking; oxidative stress 
has been proved to play a key role in the pathogenesis of 
atherosclerosis [33]. Oxidized LDL (Ox-LDL) is present in 
atherosclerotic lesions and in plasma from patients with 
CVD, and it correlates with the presence of angiographically 
documented complicated plaques [33], thus identifying pa-
tients who are at increased risk for future myocardial infarc-
tion, independently of other risk factors [34]. Since PJ con-
tains very potent antioxidants (tannins, anthocyanins), which 
are also considered potent anti-atherogenic agents, it might 
attenuate atherosclerosis development by reducing oxidative 
stress in these patients [34]. Indeed, human plasma obtained 
from healthy subjects after 2 weeks of PJ consumption (50 
mL PJ concentrate/day, equivalent to 1.5 mmol total poly-
phenols) demonstrated a significantly (p<0.01) decreased 
susceptibility to free radical-induced lipid peroxidation, in 
comparison to plasma obtained at baseline prior to PJ con-
sumption initiation, as measured by lipid peroxides forma-
tion or by total antioxidant status in serum [31,35]. Very 
recently, a study evaluated a product a new functional bever-
age based on a de-alcoholized red wine matrix supplemented 
by a pomegranate extract. This product is expected to have 
even more potent antioxidant action [36]. 
Regarding patients with metabolic syndrome (one of the 
components of which is hypertension), it has been demon-
strated that PJ exerts hypoglycaemic effects by increasing 
insulin sensitivity, inhibiting -glucosidase, and modulating 
glucose transporter type-4 function, but also lowers total 
cholesterol and exerts anti-inflammatory effects through the 
regulation of peroxisome proliferator-activated receptor 
pathways [37]. 
, numerous studies re-
ported promising results on the anticarcinogenic, and anti-
inflammatory properties of PJ, focusing on treatment and 
prevention of cancer (mainly prostate), dental conditions, 
erectile dysfunction, bacterial infections and antibiotic resis-
tance, and ultraviolet radiation-induced skin damage [38].  
In conclusion, current data suggest that long-term (at 
least for 1 year) use of PJ has a beneficial effect on BP, im-
proves endothelial function, reduces arterial stiffness and 
delays or reverses the progression of atherosclerosis. These 
effects could result in an improvement in CV and overall 
health status. Therefore, PJ might be useful as an adjunctive 
therapy for the management of hypertension on top of other 
non-pharmacological interventions or drug therapy. The use 
of PJ might reduce the number of drugs or their doses for 
patients requiring antihypertensive drug therapy. PJ might be 
more useful in patients with hypertension and high oxidative 
burden such as those with diabetes, obesity, metabolic syn-
drome or who smoke. However, our knowledge on the CV 
effects of PJ are based on studies with a small number of 
patients and limitations in their design. Therefore, future 
long-term well-designed studies with polyphenols-rich foods 
(alone or in combination), but also with isolated phenolic 
compounds would provide valuable data to establish public 
health recommendations on the use of polyphenols 
for health protection. 
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